"10.1371_journal.pone.0130699","plos one","2015-06-24T00:00:00Z","Hiroaki Matsushita; Akiko Sano; Hua Wu; Zhongde Wang; Jin-an Jiao; Poothappillai Kasinathan; Eddie J Sullivan; Yoshimi Kuroiwa","SAB Biotherapeutics, Inc., Sioux Falls, South Dakota, United States of America; Kyowa Hakko Kirin, Co., Ltd., Chiyoda-ku, Tokyo, Japan; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, United States of America; Trans Ova Genetics, Sioux Center, Iowa, United States of America; Hematech, Inc., Sioux Falls, South Dakota, United States of America","Conceived and designed the experiments: YK HM AS. Performed the experiments: HM AS HW JJ. Analyzed the data: YK HM AS HW JJ ES ZW PK. Contributed reagents/materials/analysis tools: ES YK. Wrote the paper: HM YK JJ HW ES AS ZW PK.","All authors were employees of funder Hematech, Inc. at the time of the study. Hematech, Inc., no longer exists and financial interest in this work is currently owned by SAB Biotherapeutics, Inc. Co-authors Hiroaki Matsushita, Hua Wu, Jin-an Jiao and Eddie J Sullivan are currently in paid employment by SAB Biotherapeutics Inc. Co-author Poothappillai Kasinathan is currently employed by Trans Ova Genetics. SAB Biotherapeutics, Inc is a paying customer of Trans Ova Genetics. Co-authors Akiko Sano and Yoshimi Kuroiwa are currently employed by Kyowa Hakko Kirin, Co., Ltd. The authors also have the following patent pending related to the work (Complex Chromosome Engineering for Production of Human Antibodies in Transgenic Animals, PCT No.: US2013053618). The authors have developed cattle for the production of antibodies, and have trademarked Tc (Transchromosomal) Bovine, a genetically engineered cattle, which would be considered a product of the company. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. There are no further patents, products in development, or marketed products to declare.","2015","06","Hiroaki Matsushita","HM",8,TRUE,3,4,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
